Intelligence Feed event · Policy · 2026-10-07

    Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 Readout

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present on Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is a topical anti-TNF alpha biologic candidate targeting TNFR1-mediated dry eye disease. The presentation comes as the company reaffirmed its timeline for the PREDICT-1 registrational trial, with topline clinical results expected around the end of 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-aao-ahead-of-year-end-predict-1-readout-fef740

    POLICY
    Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present on Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is a topical anti-TNF alpha biologic candidate targeting TNFR1-mediated dry eye disease. The presentation comes as the company reaffirmed its timeline for the PREDICT-1 registrational trial, with topline clinical results expected around the end of 2026.
    OCS
    Impact
    58
    OCT 7
    SIG
    85%
    OCS
    Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present on Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is a topical anti-TNF alpha biologic candidate targeting TNFR1-mediated dry eye disease. The presentation comes as the company reaffirmed its timeline for the PREDICT-1 registrational trial, with topline clinical results expected around the end of 2026.
    → Upcoming Phase 3 PREDICT-1 trial readout around year-end determines commercial viability and pipeline valuation for Oculis's topical anti-TNF alpha dry eye candidate.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present on Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is a topical anti-TNF alpha biologic candidate targeting TNFR1-mediated dry eye disease. The presentation comes as the company reaffirmed its timeline for the PREDICT-1 registrational trial, with topline clinical results expected around the end of 2026.
    Affected
    OCS
    Transmission
    Upcoming Phase 3 PREDICT-1 trial readout around year-end determines commercial viability and pipeline valuation for Oculis's topical anti-TNF alpha dry eye candidate.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech pipeline valuation sensitivity ahead of Phase 3 clinical data readoutUp1-3mOculis confirmed the PREDICT-1 registrational trial remains on track for year-end readout.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month